A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options

Xue, Weijie; Dong, Bingzi; Xie, Yuwei; Li, Pu; Gong, Zhiqi; Niu, Zhaojian

doi:10.1016/j.yexmp.2022.104832

Cited by 14 publications

(7 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination therapy of atezolizumab, an anti-PDL1 antibody, and bevacizumab, a VEGF-neutralizing antibody, is becoming the frontline treatment for HCC [ 27 , 28 ]. Immune checkpoint inhibitors (ICIs), which boost the immune system’s capacity to attack cancer cells by blocking immune checkpoint proteins like PD-1 and CTLA-4, have achieved remarkable success across various cancer types, including melanoma, lung, and gastric cancers [ 29 ]. For HCC treatment, hormilizumab (Nivolumab) and pembrolizumab (Pembrolizumab) are two approved ICIs for advanced stages, significantly enhancing the survival prospects for patients, especially those unresponsive to prior therapies.…”

Section: Discussionmentioning

confidence: 99%

Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs

Wei,

Lu,

Luo

et al. 2024

BMC Gastroenterol

View full text Add to dashboard Cite

Objectives Cuproptosis represents an innovative type of cell death, distinct from apoptosis, driven by copper dependency, yet the involvement of copper apoptosis-associated long non-coding RNAs (CRLncRNAs) in hepatocellular carcinoma (HCC) remains unclear. This study is dedicated to unveiling the role and significance of these copper apoptosis-related lncRNAs within the context of HCC, focusing on their impact on both the development of the disease and its prognosis. Methods We conducted an analysis of gene transcriptomic and clinical data for HCC cases by sourcing information from The Cancer Genome Atlas database. By incorporating cuproptosis-related genes, we established prognostic features associated with cuproptosis-related lncRNAs. Furthermore, we elucidated the mechanism of cuproptosis-related lncRNAs in the prognosis and treatment of HCC through comprehensive approaches, including Lasso and Cox regression analyses, survival analyses of samples, as well as examinations of tumor mutation burden and immune function. Results We developed a prognostic model featuring six cuproptosis-related lncRNAs: AC026412.3, AC125437.1, AL353572.4, MKLN1-AS, TMCC1-AS1, and SLC6A1-AS1. This model demonstrated exceptional prognostic accuracy in both training and validation cohorts for patients with tumors, showing significantly longer survival times for those categorized in the low-risk group compared to the high-risk group. Additionally, our analyses, including tumor mutation burden, immune function, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway enrichment, and drug sensitivity, further elucidated the potential mechanisms through which cuproptosis-associated lncRNAs may influence disease outcome. Conclusions The model developed using cuproptosis-related long non-coding RNAs (lncRNAs) demonstrates promising predictive capabilities for both the prognosis and immunotherapy outcomes of tumor patients. This could play a crucial role in patient management and the optimization of immunotherapeutic strategies, offering valuable insights for future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs

Wei,

Lu,

Luo

et al. 2024

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The results showed that hypermethylation was associated with poor clinical prognosis in HNSCC, consistent with previous findings. [ 28 ] To verify the protein expression of risk genes in HNSCC tissues, we visualized risk genes using the UALCAN database. The results showed that the expression of EFEMPP1 was up-regulated in HNSCC tissues, whereas the expression of FAM83E and SPINK7 was down-regulated in HNSCC tissues, and there was no significant difference in the expression level of CD79A.…”

Section: Discussionmentioning

confidence: 99%

Development and experimental verification of a prognosis model for disulfidptosis-associated genes in HNSCC

Li,

Tao,

Xin

et al. 2024

Medicine

View full text Add to dashboard Cite

Disulfidptosis is a newly discovered cell death pattern that has been less studied in head and neck squamous carcinoma (HNSCC). Exploring the molecular features of different subtypes of HNSCC based on disulfidptosis-associated genes (DAGs) is important for HNSCC. In addition, immunotherapy plays a pivotal role in the treatment of HNSCC. Exploring the sensitivity of immunotherapies and developing predictive models is essential for HNSCC. We analyzed the expression and mutational status of DAGs in 790 HNSCC patients and correlated the dates with clinical prognosis. HNSCC patients were divided into 2 groups based on their DAG expression. The relationship between DAGs, risk genes, and the immune microenvironment was analyzed using the CIBERSORT algorithm. A disulfidptosis risk model was constructed based on 5 risk genes using the LASSO COX method. To facilitate the clinical applicability of the proposed risk model, we constructed column line plots and performed stem cell correlation analysis and antitumor drug sensitivity analysis. Two different disulfidptosis-associated clusters were identified using consistent unsupervised clustering analysis. Correlations between multilayer DAG alterations and clinical characteristics and prognosis were observed. Then, a well-performing disulfidptosis-associated risk model (DAG score) was developed to predict the prognosis of HNSCC patients. We divided patients into high-risk and low-risk groups based on the DAG score and found that patients in the low-risk group were more likely to survive than those in the high-risk group (P < .05). A high DAG score implies higher immune cell infiltration and increased mutational burden. Also, univariate and multivariate Cox regression analyses revealed that the DAG score was an independent prognostic predictor for patients with HNSCC. Subsequently, a highly accurate predictive model was developed to facilitate the clinical application of DAG scores, showing good predictive and calibration power. Overall, we present a comprehensive overview of the DAG profile in HNSCC and develop a new risk model for the therapeutic status and prognosis of patients with HNSCC. Our findings highlight the potential clinical significance of DAG and suggest that disulfidptosis may be a potential therapeutic target for patients with HNSCC.

show abstract

“…B cells are antigen-presenting cells that promote cytokine secretion and promote liver cancer metastasis. They can also directly kill tumor cells by secreting granzyme B (Xue et al 2022 ), ( Chen et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Development of a novel lncRNA-derived immune gene score using machine learning-based ensembles for predicting the survival of HCC

Cai,

Li,

Zhu

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Long noncoding RNAs (lncRNAs) are implicated in the tumor immunology of hepatocellular carcinoma (HCC). Methods HCC mRNA and lncRNA expression profiles were used to extract immune-related genes with the ImmPort database, and immune-related lncRNAs with the ImmLnc algorithm. The MOVICS package was used to cluster immune-related mRNA, immune-related lncRNA, gene mutation and methylation data on HCC from the TCGA. GEO and ICGC datasets were used to validate the model. Data from single-cell sequencing was used to determine the expression of genes from the model in various immune cell types. Results With this model, the area under the curve (AUC) for 1-, 3- and 5-year survival of HCC patients was 0.862, 0.869 and 0.912, respectively. Single-cell sequencing showed EREG was significantly expressed in a variety of immune cell types. Knockdown of the EREG target gene resulted in significant anti-apoptosis, pro-proliferation and pro-migration effects in HepG2 and HUH7 cells. Moreover, serum and liver tissue EREG levels in HCC patients were significantly higher than those of healthy control patients. Conclusion We built a prognostic model with good accuracy for predicting HCC patient survival. EREG is a potential immunotherapeutic target and a promising prognostic biomarker.

show abstract

A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options

Cited by 14 publications

References 83 publications

Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs

Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs

Development and experimental verification of a prognosis model for disulfidptosis-associated genes in HNSCC

Development of a novel lncRNA-derived immune gene score using machine learning-based ensembles for predicting the survival of HCC

Contact Info

Product

Resources

About